New York, Aug. 4 - Osiris Therapeutics, Inc. priced its $38.5 million initial public offering at the low end of the expected range.
The Baltimore-based stem cell therapeutic company sold 3.5 million shares at $11.00 each, at the bottom of the $11 to $13 talk.
The deal has an over-allotment option for 525,000 shares.
Jefferies & Co. was bookrunner for the sale, with Lazard Capital Markets as joint lead and Leerink Swann & Co. as co-manager.
Osiris' stock began trading on the Nasdaq Global Market under the symbol "OSIR."
Proceeds will be used to fund business growth, including clinical trials and preclinical research and development, to repay a $20.6 million promissory note and for general corporate purposes.
| Issuer: | Osiris Therapeutics, Inc.
|
| Issue: | Initial public offering of common stock
|
| Amount: | $38.5 million
|
| Shares: | 3.5 million
|
| Greenshoe: | 525,000
|
| Price: | $11.00
|
| Bookrunner: | Jefferies & Co.
|
| Pricing date: | Aug. 3, after close
|
| Symbol: | Nasdaq: OSIR
|
| Talk: | $11.00 to $13.00
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
